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Reactive urothelial atypia (RUA) can be difficult to differen-
tiate from dysplastic urothelium. The goal was to evaluate
the efficacy of cytokeratin 20 (CK20), Ki-67 and E-cadherin





50 non-neoplastic urothelia (25 normal, 25 reactive urothe-
lial atypia (RUA)) and 17 atypia of unknown significance
(AUS) cases were evaluated. All cases were stained with
monoclonal antibodies against Ki-67, CK20 and E-Cad. All
(100%) normal urothelia showed normal staining patterns.
In the CIS group, 86%, 82% and 20% of cases showed
abnormal expression with CK20, Ki-67 and E-Cad, respec-
tively. Both Ki-67 and CK20 were positive in 68% of cases.
In the RUA group, 96%, 72% and 100% of cases showed
normal expression patterns with CK20, Ki-67 and E-Cad,
respectively. Of 28% RUA cases with increased Ki-67, none
demonstrated abnormal CK20 or E-Cad expression. In the
AUS group, 47% demonstrated abnormal CK20 and
increased Ki-67 expression, suggestive of urothelial dyspla-
sia/CIS, 29% were negative with both, suggestive of RUA,
and the remaining 24% cases could not be resolved. In
summary, abnormal CK20 is a useful adjunct to morphology
for confirming dysplasia. Ki-67 by itself is a less reliable
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The 2004 World Health Organization (WHO) consensus
committee classifies flat urothelial lesions with atypia as
reactive atypia, atypia of unknown significance (AUS),









dysplasia (UD) is defined by cytological and architectural
changes felt to be preneoplastic yet falling short of the diag-
nostic threshold of CIS. AUS is a descriptive term reserved
for cases in which dysplasia cannot be ruled out with cer-
tainty, due to a greater degree of pleomorphism and/or hyper-




UD and CIS are precursor lesions of invasive carcinoma
and their presence, especially CIS, is associated with a high




Morphology alone is frequently insufficient to differentiate
dysplasia/CIS from reactive urothelial atypia (RUA) in the
setting of inflammatory/post-therapy changes. However, this
distinction is critical because it has both therapeutic and
prognostic implications. In diagnostically difficult situations of
AUS, an objective marker of UD/CIS to augment histology
could be of immense help to surgical pathologists in distin-
guishing RUA from UD/CIS. Recent studies have demon-
strated the utility of cytokeratin 20 (CK20), Ki-67 and p53




E-Cadherin (E-Cad), an epithelial cell adhesion molecule,




The goal of the current study was to validate the clinical
utility of a select panel of CK20, Ki-67 and E-Cad as markers
of dysplastic urothelial lesions. There has been no study to
date, which has evaluated the potential utility of these mark-
ers in the work-up of clinically difficult cases. Therefore, the
second objective of the present study was to assess the
practical diagnostic utility of immunohistochemistry in resolv-





Fifty cases of non-neoplastic urothelia including 25 benign
normal urothelia and 25 with morphologically unequivocal
reactive urothelial changes/atypia (RUA) and 50 cases of
unequivocal CIS from biopsy and resection specimens were
selected from the University of Michigan surgical pathology
files between 1996 and 2003. Of the 25 samples of RUA, 13
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cases were from cystectomy specimens (seven patients had
received therapy that included bacillus Calmette-Guerin
(BCG)/radiation/chemotherapy prior to cystectomy) and 12
cases were biopsy specimens (10 cases had no prior history
of tumor/therapy and two cases were post-BCG/mitomycin
treatment). Of 50 CIS cases, three cases demonstrated
pagetoid spread of CIS and three showed clinging CIS
morphology.
In addition, 17 diagnostically difficult cases (AUS), which
could not be resolved as reactive atypia versus UD/CIS,
based solely on morphology were also evaluated. Ten of
these 17 cases had been obtained in a post-therapy setting
(eight cases with BCG/mitomycin/interferon and two after
chemotherapy/radiation). Follow-up information (repeat
biopsy/cystectomy) was available in 10 of 17 AUS cases. Two
authors (LPK and RBS) reviewed the original HE slides of all
cases, using the 2004 WHO committee diagnostic criteria, to







Immunohistochemistry (IHC) was performed using refined





DakoCytomation, Carpinteria, CA, USA) for CK20 and Ki-67.
Following paraffin removal and hydration, slides were treated
with protease 1 enzyme pretreatment for 16 min (for CK20),
Tris (0.25 mol/L)-ethylenediamine tetra-acetic acid (EDTA;
0.1 mmol/L) buffer, pH 9.0 in a microwave pressure cooker
for 15 min (for Ki-67) and 0.01 mol/L citrate, pH 6.0 in a
microwave pressure cooker for 10 min (for E-Cad) for optimal
antigen retrieval before immunostaining. Cases were stained
with monoclonal antibodies against CK20 (DakoCytomation)




C, Ki-67 (MIB-1 clone;





Cad (Zymed, San Francisco, CA, USA) at 1:400 dilution for





from formalin-fixed paraffin embedded blocks. A Ventana
Basic DAB Detection Kit was used according to manufac-
turer’s specifications for CK20 and Ki-67 and staining was
performed on the Ventana ES autostainer (Ventana Medical
Systems, Tucson, AZ, USA). A Biotin free tyramide signal
amplification system (CSA II, DakoCytomation) was used
according to manufacturer’s specifications for E-Cad and
staining was done on the Dako autostainer (DakoCytoma-
tion). Sections were then counterstained with Gills hematox-
ylin. Positive controls of colonic adenocarcinoma, lobular
carcinoma of breast and tonsil were used for CK20, E-Cad
and Ki-67, respectively. The negative controls had primary
antibody replaced by buffer.
Two authors (L.P.K. and R.B.S.) interpreted the IHC results
and an average score was used for evaluation.
 
Normal and abnormal expression patterns of CK20
 
Based on previously reported criteria, superficial umbrella
cell staining pattern of neoplastic urothelium was interpreted




 In the majority of
cases, the staining was continuous but occasional cases
showed discontinuous staining of umbrella cells.
Abnormal expression of CK20 in CIS was characterized by
diffuse, strong full thickness staining of dysplastic urothelium
(Fig. 1H).
 
Normal and abnormal expression patterns of Ki-67
 
We utilized a visual estimate to quantify Ki-67 expression.














cells staining was designated as unequivocal abnormal over-
expression of Ki-67 (Fig. 1I). All staining reactions between
10 and 50% were classified as equivocal. We used this three-
tier system to minimize interobserver variability in evaluation
of normal and abnormal expression patterns.
 
Normal and abnormal expression patterns of E-Cad
 









90% were characterized as





Immunoreactivity patterns in normal urothelium
 
All 25 cases (100%) of normal urothelia had normal expres-
sion patterns with all three antibodies (Fig. 1A–C).
 
Immunoreactivity patterns in reactive urothelium
 
Ninety-six percent (24/25) of morphologically unequivocal
cases of RUA showed normal expression patterns with both
CK20 and E-Cad (Table 1). One case (4%) of RUA had focal
full thickness staining with CK20 that was reasonable to
interpret as non-specific because it was patchy with benign
morphology.
Ki-67 produced mixed results (Table 1). While 72% (18/25)




10% basal cell staining), 28%
(7/25) of cases showed increased expression of Ki-67,
especially when associated with intense inflammation
(Fig. 1D–F).
 
Immunoreactivity patterns in CIS
 
In the CIS group, 86% (43/50) had abnormal CK20 expres-
sion and 14% (7/50) were negative with CK20 (Fig. 1G–I;
 




Table 1). In all three cases of CIS with pagetoid pattern,
CK20 stained only the dysplastic CIS cells, while the
surrounding urothelium was negative (Fig. 1J–K). In two of
three cases of clinging CIS, CK20 was strongly positive
(Fig. 1M–N).
All seven cases of CIS that were negative with CK20,
including one case that had a clinging pattern, had unequiv-
ocal over-expression of Ki-67.
A total of 82% of cases (41/50) had unequivocal over-
expression of Ki-67 while 18% (9/50) had equivocal (10–




10% expression of KI-67.
A total of 20% (10/50) of CIS cases had aberrant E-Cad
expression (Table 1).
In summary, all cases of CIS had abnormal expression of
at least one marker. Both CK20 and Ki-67 were positive in
68% of cases (34/50) and in no case was E-Cad the sole
abnormal marker.
 
Immunoreactivity patterns of 17 cases of AUS
 
A total of 8/17 cases (47%) of AUS had abnormal CK20





50%) of Ki-67. In three cases,
abnormal CK20 expression with equivocal Ki-67 expression
(30–40%) was noted (Fig. 2A–C). All these cases were
favored to be UD/CIS.
A total of 5/17 cases (29%) were negative with both anti-
bodies and were thought to be reactive.
We were unable to categorize 4/11 (24%) AUS cases,
three of which were obtained in a post-therapy setting, with
this panel of immunostains. Negative CK20 and increased
expression of Ki-67 was noted in three cases. One of these
three cases had focal abnormal expression of CK20 in a
morphologically benign area with no staining observed in the
focus of interest, while Ki-67 was unequivocally over-
expressed in the focus of interest. The fourth and last case,
taken in a post-therapy setting, was negative for Ki-67 while
CK20 was difficult to interpret with extremely focal staining
in the denuded atypical cells (Table 2).
Follow-up information was available in 10 AUS cases
where a repeat biopsy (six cases) or cystectomy (four cases)
was performed within 8–16 weeks of original biopsy. Of these
10 cases, CIS was confirmed in seven cases and three
follow-up biopsies confirmed impression of reactive atypia. In
one case, the patient developed a second colonic carcinoma,









 The diagnosis of CIS is based on




Immunohistochemistry reactivity patterns in normal urothelia, RUA and CIS
Diagnosis
CK20 Ki-67 E-Cad
































; CK, cytokeratin; E-Cad, E-cadherin; RUA, reactive urothelial atypia.








Immunohistochemistry reactivity patterns of 17 cases of
AUS
Immunoprofile RUA UD/CIS Unresolved










/equivocal Ki-67 – 3 –
CK20–/equivocal Ki-67 – – 3













) Urothelium with atypia such that dysplasia
























































) Abnormal expression pattern of CK20 in CIS characterized by diffuse,

















































pleomorphism and mitotic activity. These cytologic features
need not involve the full thickness of urothelium to qualify for




 Although these morphologic criteria
are very useful to diagnose CIS with confidence, this diag-
nosis can frequently become challenging in cases where the
differential diagnosis includes reactive/therapy atypia. Cer-
tain morphologic variants of CIS including pagetoid CIS and
clinging CIS, as well as dysplastic lesions showing apprecia-
ble cytologic atypia not severe enough to merit the diagnosis
of CIS, can also create diagnostic difficulties. The distinction
of UD/CIS from therapy atypia is critical because it has both
therapeutic as well as prognostic importance. Patients with
CIS are typically initially treated with intravesical BCG. Intra-
vesical chemo/immunotherapy is used in a subset of patients
who are refractory to BCG. Persistent dysplasia/CIS in a
post-therapy setting is considered to represent therapy failure





 Hence, specific markers of UD/CIS would be
of great utility to surgical pathologists as adjuncts to morphol-
ogy in this setting.
Several groups have attempted to delineate markers of
UD/CIS, and CK20, p53, Ki-67 and CD-44 have been





 Overall, in the search for reliable markers of urothe-





 While confined to superficial umbrella cells in
normal urothelium, CK20 shows diffuse full thickness stain-
ing in 72–81% of cases of CIS and is also expressed in 22–




Ki-67, a nuclear protein associated with cell proliferation,
has been shown to be associated with tumor grade, stage,





studies have reported slightly increased sensitivity of Ki-67








. demonstrated utility of CD-44 in reactive
urothelium with diffuse membranous full-thickness staining




However, in their study 44% cases of CIS also showed resid-
ual basal cell expression with this antibody.
Studies addressing the role of E-Cad in CIS have reported









utility of E-Cad as a marker of disease progression and
survival and reported loss or heterogeneous E-Cad expres-
sion in 32% of CIS cases without associated muscle invasive





 Sun and Herrera showed E-Cad expression to be





 In general, loss of E-Cad appears to be asso-
ciated with high grade and advanced stage of urothelial car-




Utilizing a panel of CK20, Ki-67 and E-Cad to analyze the
present cases, we found CK20 and Ki-67 to be useful markers
of UD/CIS. The majority of CIS cases (86%) had abnormal
expression of CK20 (Fig. 1G–I) while all samples of benign
urothelium and 96% of morphologically clear-cut RUA were
negative (Table 1). Although CK20 appears to be a fairly
specific marker of urothelial dysplasia, a small subset of
morphologically clear-cut CIS (14% in the present study) can
be negative with this antibody. This observation reflects sim-
ilar findings by other groups who demonstrated that 19–28%




 However, increased Ki-67 expres-
sion can usually resolve this problem. In our study, all CIS
cases negative with CK20 showed unequivocal over-
expression with Ki-67. In general, CIS showing discohesive
dysplastic cells, pagetoid spread and clinging CIS had abnor-
mal CK20, making this a useful marker for the diagnosis of
these variants of CIS (Fig. 1J–O), although one of the present
cases of clinging CIS did not express CK20. We did not
include cases that we considered to be urothelial dysplasia
(which had atypia that was felt to be preneoplastic yet short
of diagnostic threshold for CIS), because the intraobserver
reproducibility for this diagnosis is not high. The distinction
between UD and CIS is essentially one of morphologic
threshold. The aim of the present study was to see if this
panel of immunostains would be able to distinguish reactive
atypia versus dysplastic urothelial lesions; not to separate
the spectrum of dysplastic urothelial lesions. We believe this
panel of CK20 and Ki-67 cannot distinguish between UD and
CIS. Hence, we refer to this spectrum collectively as UD/CIS.
Although virtually all cases (96%) of RUA were negative
with CK20 beneath the superficial umbrella layer, we had one
case of morphological clear-cut RUA showing focal full-
thickness CK20 expression. It is important to realize that on
rare occasions such abnormal CK20 staining may occur,
therefore correlation with morphology is critical. Another area
of difficulty encountered with CK20 interpretation is when
urothelium is fragmented and/or denuded. CK20 expression
in the superficial umbrella cells of fragmented epithelial frag-
ments opposed to each other may give a false impression of
a full-thickness staining pattern of UD. Clinging pattern of CIS
may also cause some difficulty in interpretation. In these
situations, diffuse full-thickness staining pattern is not appli-
cable because the denuded urothelium is usually lined by a
single layer of atypical hyperchromatic cells and hence,
expression of CK20 by these basally located atypical cells is
considered to be abnormal expression.
In our experience, Ki-67 produced mixed results. While
82% of CIS had unequivocal over-expression of Ki-67, 28%
of morphologically clear-cut RUA also had increased expres-
sion, especially when associated with severe inflammation.
Hence, caution must be exercised when interpreting this
antibody in an inflamed urothelium and these results demon-
strate the limitation of utilizing Ki-67 as a sole marker of UD/
CIS. In the present series, 18% of CIS cases had equivocal
expression of Ki-67, varying between 30 and 40%. Our
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50% expression of Ki-67 (82% in the present study vs 38%).
This could be another potential problem with Ki-67, because
issues of interobserver reproducibility in evaluating Ki-67
expression in borderline situations (e.g. 40–50% Ki-67
expression) may occur.
Because CIS cells have traditionally been known to be
discohesive and because E-Cad is an important cell adhe-
sion molecule, we postulated that E-Cad expression might
be aberrantly low in CIS. In the present study aberrant E-Cad
expression was present in 20% cases of CIS. Although in the
present study all cases of CIS having aberrant E-Cad expres-
sion were associated with invasive disease, the converse
was not true, that is, not all cases of CIS associated with
invasive disease had aberrant E-Cad expression. Overall, our
impression was that E-Cad by itself did not appear to be a
very useful marker of UD and hence, we did not utilize this
marker on the present cases of AUS.
The greatest value of a panel of immunostains would be
the ability to resolve cases of AUS. Based on our results, we
utilized a panel of CK20 and Ki-67 to resolve cases of AUS.
To our knowledge, no study so far has analyzed the utility of
these markers in clinically difficult cases. It is important to
realize that AUS is not a disease or a diagnostic entity but
merely a descriptive term used in diagnostically difficult
cases. In the present study, 10 cases of AUS could be cate-
gorized as reactive versus dysplastic with the help of both
CK20 and Ki-67 (Table 2). Our impression was confirmed in
five cases by follow-up biopsies (four cases) or subsequent
cystectomy (one case). In three cases, thought to be UD/CIS
based on abnormal CK20 expression with equivocal Ki-67
expression (Fig. 2A–C), diagnosis of CIS was confirmed after
subsequent cystectomy (two cases) or repeat biopsy (one
case). We were unable to definitely categorize four cases of
AUS, using this panel, as reactive versus dysplastic. Three
cases had Ki-67 over-expression with negative CK20 in the
area of interest, where the risk of over-interpretation of UD
using Ki-67 as a sole marker of UD was high. Follow up with
a repeat biopsy (one case) and cystectomy (one case) dem-
onstrated CIS in two of these three cases. In the fourth case,
CK20 was non-contributory and Ki-67 was negative. The
patient subsequently developed a second unrelated colonic
neoplasm but no follow up is available as yet regarding uri-
nary bladder.
Based on our experience this panel of immunostains would
be of greatest utility in the following clinical scenarios: (i)
biopsies taken in a post-therapy setting where the differential
diagnosis includes reactive/therapy atypia versus UD/CIS (in
such situations an immunoprofile of CIS (diffuse strong full
thickness CK20 expression and Ki-67 over-expression) in
conjunction with morphology may offer significant advantage
in supporting diagnosis of CIS; in the present study, follow
up with repeat biopsy or cystectomy confirmed presence of
CIS in 5/8 AUS cases with immunoprofile of CIS but further
study with a larger series of AUS cases with a longer follow-
up would be required to confirm this finding and evaluate if
this panel can separate the spectrum of dysplastic urothelial
lesions); (ii) to confirm diagnosis of CIS with unusual mor-
phology (e.g. pagetoid CIS and clinging CIS); and (iii) to
augment level of confidence in cases where morphology in
general favors CIS and an immunoprofile characteristic of
CIS would lend further support to this impression.
In summary, CK20 is a reliable and relatively specific
marker of UD in conjunction with morphology. In cases of
diagnostically challenging biopsies, diffuse strong full-thick-
ness staining of urothelium with CK20 in the area of interest
supports a diagnosis of UD/CIS. However, a negative stain-
ing may not always exclude the diagnosis, especially in the
absence of any superficial umbrella cells in biopsy as a
reliable internal control. Ki-67 appears to be more reliable in
conjunction with both CK20 and morphology to augment
confidence in the diagnosis of UD. Caution must be exercised
when interpreting Ki-67 as a sole marker of UD especially in
the setting of a negative CK20, because a subset of RUA
may over-express Ki-67 especially when associated with
severe inflammation. This panel cannot differentiate between
UD and CIS. E-Cad by itself does not appear to be a useful
marker in this setting. Based on our results we recommend
the panel of CK20 and Ki-67 immunostains in conjunction
with morphology to aid in the distinction of reactive urothelial
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